brivaracetam   Click here for help

GtoPdb Ligand ID: 9041

Synonyms: 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide | Briviact® | compound 83α [1] | UCB 34714 [3] | UCB-34714 | UCB34714
Approved drug
brivaracetam is an approved drug (EMA & FDA (2016))
Compound class: Synthetic organic
Comment: Brivaracetam is a 4-n-propyl analogue of levetiracetam with anticonvulsant properties [3]. Like levetiracetam this drug inhibits synaptic vesicle protein 2A (SV2A), but with 10X higher binding affinity. Brivaracetam is brain penetrant and has a fast onset of action [2]. It can also inhibit sodium channels.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 63.4
Molecular weight 212.15
XLogP 0.8
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCCC1CN(C(=O)C1)C(C(=O)N)CC
Isomeric SMILES CCC[C@H]1CN(C(=O)C1)[C@H](C(=O)N)CC
InChI InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
No information available.
Summary of Clinical Use Click here for help
Brivaracetam was EMA and FDA approved in 2016 as an adjunctive therapeutic for the treatment of partial-onset seizures in patients with epilepsy. Use in pediatric patients age four years and older was FDA approved in May 2018.
External links Click here for help